一項(xiàng)新的研究發(fā)現(xiàn),，與當(dāng)前血壓藥物能防止大腸癌相反,，服用β-受體阻滯劑治療高血壓并不減少一個(gè)人發(fā)展罹患大腸癌的風(fēng)險(xiǎn),。相關(guān)研究論文發(fā)表在Cancer雜志上,，該研究還表明即使長(zhǎng)期使用β受體阻滯劑的亞型并無(wú)明顯減少大腸癌的危險(xiǎn),。
近年來(lái)，研究者們認(rèn)為β受體阻滯劑的服用可能與癌癥的風(fēng)險(xiǎn)降低有關(guān),。這個(gè)理論源于動(dòng)物實(shí)驗(yàn)研究和實(shí)驗(yàn)室研究中發(fā)現(xiàn)應(yīng)激激素去甲腎上腺素能促進(jìn)癌細(xì)胞的生長(zhǎng)和擴(kuò)散。β受體阻滯劑抑制去甲腎上腺素,，所以認(rèn)為它能具有抗癌特性,。
β-受體阻滯劑對(duì)大腸癌風(fēng)險(xiǎn)的影響在先前的一些研究中實(shí)際上得出了不一致的結(jié)果。為了更深入解決這一問題,，德國(guó)癌癥研究中心的Michael Hoffmeister博士和他的同事們對(duì)2003年至2007年與1762例大腸癌和1708未患癌癥的人進(jìn)行了隨訪研究,。
考慮某些病人特征（如體重和吸煙狀況）和其他可能影響結(jié)果的因素后，研究人員并沒有發(fā)現(xiàn)使用β受體阻滯劑和大腸癌風(fēng)險(xiǎn)降低之間的聯(lián)系,?？偟膩?lái)說(shuō)，這項(xiàng)研究結(jié)果并不支持降血壓藥物防止大腸癌這一假設(shè),。（生物谷：Bioon.com）
doi:10.1002/cncr.26727
PMC:
PMID:
Beta blocker use and colorectal cancer risk?
Lina Jansen MSc, Janina Below, Jenny Chang-Claude PhD, Hermann Brenner MD, MPH, Michael Hoffmeister PhD
Abstract
BACKGROUND:
Recently, it has been postulated that long-term use of beta blockers might decrease the risk of certain types of cancer because of weakening of norepinephrine signaling. Previous studies on colorectal cancer (CRC) yielded inconsistent results, but lacked information on covariates. Thus, the authors investigated the association of beta blocker use and CRC risk in a large population-based case-control study (DACHS study).
METHODS:
Between 2003 and 2007, information on beta blocker use and potential confounders was collected by personal interviews for 1762 CRC cases and 1708 control individuals from Germany. The association of CRC risk and beta blocker use and subclasses of beta blockers was estimated by multiple logistic regression. In addition, site- and stage-specific analyses were performed.
RESULTS:
After adjustment for covariates, no association was observed with beta blocker use (odds ratio [OR], 1.05; 95% confidence interval [CI], 0.86-1.29) or with duration of beta blocker use. Also, the analysis by subclasses of beta blockers (cardioselectivity) and active ingredients (metoprolol, bisoprolol, carvedilol, and atenolol) or by CRC subsite showed no associations. In stage-specific analyses, long-term beta blocker use (6+ years) was associated with a significantly higher risk of stage IV CRC (OR, 2.02; 95% CI, 1.25-3.27).
CONCLUSIONS:
Our adjusted results do not support the hypothesis that beta blocker use is associated with decreased risk of CRC. In contrast, we found a positive association of long-term beta blocker use and risk of stage IV CRC. The latter result should be further evaluated in future studies.
